Key result
MRAs reduce mortality and hospitalization in HF patients with appropriate monitoring.
Why the study?
Epidemiological data on the burden of heart failure from the Indian subcontinent is scarce.
This expert consensus document outlines the pathophysiological rationale and clinical application of MRAs (spironolactone and eplerenone) for heart failure management, particularly in the Indian subcontinent.
MRAs support mortality reduction in HF with monitoring; confirms consensus while leaving region-specific implementation open.
Epidemiological data from the Indian subcontinent on the burden of Heart failure (HF) is scarce. Mineralocorticoid receptor antagonists (MRAs) are usually used in the management of HF and hypertension. A consortium of experts reviewed and opined on the pathophysiological role of aldosterone in HF and its cascading effects on the heart in terms of cardiac fibrosis, cardiac hypertrophy, and remodeling, increased propensity to cause arrhythmias in addition to its effect on sodium and water retention. This expert opinion document highlights the various mechanisms of action of MRAs. It provides clinical experience and practice-based expert opinion on the use of spironolactone and eplerenone in patients with HF. The role of MRAs in diabetic patients with HF has also been profiled.
No takes yet. Share an insight, caveat, or question.
Jadhav et al. (2023) conducted a review in Heart Failure. Mineralocorticoid Receptor Antagonists (spironolactone, eplerenone) was evaluated. Mineralocorticoid receptor antagonists, such as spironolactone and eplerenone, are recommended in heart failure patients to reduce mortality and hospitalization risks with appropriate monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: